Catalyst Funds Management Pty LTD Biocryst Pharmaceuticals Inc Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 24,900 shares of BCRX stock, worth $186,501. This represents 0.04% of its overall portfolio holdings.
Number of Shares
24,900Holding current value
$186,501% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
279Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$152 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$149 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$88.9 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$68 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$66.3 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.39B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...